Literature DB >> 6352078

Results of coronary artery surgery in patients with poor left ventricular function (CASS).

E L Alderman, L D Fisher, P Litwin, G C Kaiser, W O Myers, C Maynard, F Levine, M Schloss.   

Abstract

We identified 420 medically treated and 231 surgically treated patients (coronary graft plus myocardial surgery in 30%) who had severe left ventricular dysfunction manifest by an ejection fraction below 0.36 and markedly abnormal wall motion. Compared with medically treated patients, those treated surgically had more severe angina (56.7% vs 29.0% class III or IV; p less than .001), less heart failure as predominant symptom (11.1% vs 18.8%; p less than .003), more severe coronary disease (66.7% vs 50.2% three-vessel disease; p less than .001), a greater concentration of left main coronary artery lesions greater than 70% (12.6% vs 3.8%: p less than .001), and a greater estimated extent of jeopardized myocardium (p less than .001). Multivariate regression analysis of survival, which adjusts for the above covariates, showed that surgical treatment prolonged survival (p less than .05), although it ranked below severity of heart failure symptoms, age, ejection fraction, and left main stenosis greater than 70% in determining prognosis. Surgical benefit was most apparent for patients with ejection fractions below 0.26 who had a 43% 5 year survival with medical treatment vs 63% with surgery. Surgically treated patients experienced substantial symptomatic benefit compared with medically treated patients if their presenting symptoms were predominantly angina; however, there was no relief of symptoms caused primarily by heart failure. We conclude that patients with predominantly ischemic pain symptoms, despite poor left ventricular function, benefit from surgery; however, operative mortality in this high-risk subset must equal or better the 6.9% obtained in this study.

Entities:  

Mesh:

Year:  1983        PMID: 6352078     DOI: 10.1161/01.cir.68.4.785

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  109 in total

Review 1.  Fluorine-18-deoxyglucose SPECT and coincidence imaging for myocardial viability: Clinical and technologic issues.

Authors:  V Dilsizian; S L Bacharach; M M Khin; M F Smith
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

2.  Hibernating myocardium in post-ischaemic heart failure: pathophysiology, identification and revascularisation.

Authors:  D Pagano
Journal:  Ann R Coll Surg Engl       Date:  2000-07       Impact factor: 1.891

3.  Assessment of myocardial viability after myocardial infarction.

Authors:  Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

4.  The quest for myocardial viability: Is there a role for nitrate-enhanced imaging?

Authors:  Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2003 Nov-Dec       Impact factor: 5.952

Review 5.  Surgery for hibernation.

Authors:  J Pepper
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

6.  Risk stratification for open heart surgery: trial of the Parsonnet system in a British hospital.

Authors:  S A Nashef; F Carey; M M Silcock; P K Oommen; R D Levy; M T Jones
Journal:  BMJ       Date:  1992-10-31

Review 7.  Management issues for patients with coronary artery disease and heart failure.

Authors:  Andrew D Feingold; David DeNofrio
Journal:  Curr Cardiol Rep       Date:  2003-05       Impact factor: 2.931

8.  Long-term survival of patients with low ejection fraction: surgical versus medical management.

Authors:  V Balu; L Szmedra; D Dean; J Bhayana
Journal:  Tex Heart Inst J       Date:  1988

9.  Determinants of 10-year survival after primary myocardial revascularization.

Authors:  D M Cosgrove; F D Loop; B W Lytle; C C Gill; L A Golding; C Gibson; R W Stewart; P C Taylor; M Goormastic
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

Review 10.  Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease.

Authors:  N K Sabharwal; A Lahiri
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.